| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 | Jun, 2024 |
| Sales | 75 | 74 | 73 | 75 | 75 |
| Sales Growth | +1.10% | +1.11% | -2.17% | unch | +1.10% |
| Net Income | -486 | -1,069 | -626 | -5,655 | -733 |
| Net Income Growth | +54.52% | -70.86% | +88.93% | -671.06% | +34.65% |
Asep Medical Holdings Inc.
(ASEP.CN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ASEP Medical Holdings Inc is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. Diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments. Its Diagnostic has developed a novel diagnostic assay for the early and rapid risk assessment of sepsis. Therapeutic offering: Patented peptide technology targets infection-causing biofilms and reduces inflammation.
Fiscal Year End Date: 12/31